chrisvoncsefalvay/vaers-outcomes huggingface dataset:
rash that she had in the upper body/had an upper body rash on her front and back; The rash is itchy; The red color of the rash faded a little bit but it came back and then there are little dots and some of them have become big lumps; This a spontaneous report from a contactable consumer(patient) via medical information team. A 59-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: Solution for injection, Lot number: ER8733, Expiry Date: Unknown) via an unspecified route of administration, administered in left upper arm on 01Apr2021(at the age of 59-year-old) as dose 1, single for COVID-19 immunization. Medical history included Vitamin D low and Immune enhancement therapy (she heard it increases the immune system) both are from an unknown date and unknown if ongoing. Concomitant medications included Colecalciferol (VITAMIN D) 50,000 grams weekly via an unspecified route of administration Indicated for Vitamin D low from an unknown date (Started it several years ago) unknown if ongoing, Ascorbic acid(VITAMIN-C) 500 mg once a day and Tocopherol(VITAMIN E)180 mg once a day both are via an unspecified route of administration from an unknown date (Started taking it at the beginning of the year) indicated for increasing immune system( she heard it increases the immune system) unknown if ongoing. It was reported that on 05Apr2021 about 22:00 or 23:00 patient had an upper body rash on her front and back and she did not know if it was related to the vaccine because it had been a few days. The rash was itchy, but she did not touch it because she did not want to make it worse. The red color of the rash faded a little bit but it came back and then there were little dots and some of them have become big lumps. The reporter also had itching on her upper arms. Reporter queried that was this related to the vaccine, and how long would this last. Reporter stated scheduled to receive the second dose of the Pfizer-BioNTech COVID-19 Vaccine on 22Apr2021. And queried can still take the second dose. Patient stated she was taking COVID vaccine for Prevention of COVID and everyone had a turn, and it was her turn. Reporter seriousness for upper body rash was Unspecified. There was no Investigation Assessment. Outcome of the events was not recovered.  No follow up attempts are possible. No further information is expected.
This case was reported by a healthcare professional and described the occurrence of radiating pain in arm in a female subject of unspecified age who was vaccinated with FLUARIX (GlaxoSmithKline). On 6 October 2012 the subject received 1st dose of FLUARIX (.5 ml, unknown, right arm). It was reported that the needle that was used for the injection was a BD 30 gauge ? inch. In October 2012, less than one month after vaccination with FLUARIX, the subject experienced radiating pain in arm and injection site pain. The healthcare professional reported the subject received FLUARIX on 06 October 2012 and came to the office on 17 October 2012 complaining of continuing radiating pain at the site of injection. The subject went to the emergency room but did not stay overnight. The subject wanted to get an x-ray of the area but she did not get an x-ray. The healthcare professional confirmed that the subject did not have any redness or swelling at the site of injection. At the time of the report no other details were provided. At the time of reporting the radiating pain at the site of injection were unresolved. Follow-up information was received on 14 November 2012 via healthcare professional who reported the subject continues to have pain of injection site that started on 06 October 2012. On 17 October 2012, the subject went to the emergency room due to the continued pain at right deltoid injection site. An x-ray of the right arm/shoulder was performed and "'negative' the subject was given a sling". At the time of the report the outcome of pain at injection site was improved; the reporter did not comment on the outcome of radiating pain in arm.
Mild fever only around 99.6-100, slight chills, slightly tired and very mild headache
fever,myalgia. pt received rabies vaccine ist dose on 01/27/09 and second dose on 02/03/09, and was scheduled for third dose 02/23/09. When pt presented for third dose, complained of fever and myalgia from 2nd dose.  3rd dose was not administered. It is undertermined when/if pt will receive 3rd dose
Within two hours of vaccination, the left arm had begun swelling, with associated pain, and fever.  This was post work hours, and had already gone home, took Ibuprofen 400mgs, went to bed.  Awakened in night several times, with sweats (102 Degrees, F), pain, and lymph node swelling.  Called into sick, informed LeadWorker as to what was happening.  Intermittent sweats, fevers and pain from swelling through day.  Fever finally broke that evening, took more Ibuprofen 400mg, slept through night, arm swollen, painful.  Swelling decreased next morning, called in sick due to unilateral pain, continuing swelling, numbness in arm and hand (L).  Obtained appointment with MD that PM. Rested through rest of day, swelling decreasing, cont. numbness, pain, "pins and needles" effects.  MD diagnosed cellulitis secondary to vaccination, provided scrip for Bactrim DS and Keflex, and note to return to work the next day, which I did.  Swelling has greatly decreased, some discoloration of arm, pins and needles and intermittent numbness still occurring.
Chronic bilateral temporal headache starting 48 hours after injection.  Suspected a new COVID infection, but tested negative 7 days after headache began.  With analgesics, headaches are now intermittent. On day 10 after injection, bilateral tinnitus, worsening of left arm and hand paresthesia.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age. No information on patient's pertinent medical history and drug reactions or allergies was provided. On an unknown date, the patient was vaccinated with an intramuscular injection of ZOSTAVAX (dose, frequency, lot # and expiry date were not provided) rather than subcutaneous injection, at her physician's office. On an unknown date, the patient experienced reddened area around the injection site and felt that the injection was bleeding a little more than she had expected. The outcome of events was unknown. The causality between the events and ZOSTAVAX was not provided. Additional information is not expected, as there was no consent to contact the physician.
Anaphylactic reaction immediately after vaccination; This is a spontaneous report from a contactable consumer (patient). A 22-year-old non-pregnant female patient received the first dose of BNT162B2 (BNT162B2; Batch/Lot number was not reported), via an unspecified route of administration, administered in right arm on 18Mar2021 16:00 at single dose for COVID-19 immunization. The patient's medical history included asthma, known allergies to legumes, soy, egg, and tree nuts. The patient's concomitant medications were not reported. The facility type vaccine was hospital. The patient had no other vaccine in four weeks. The patient experienced anaphylactic reaction immediately after vaccination on 18Mar2021 16:00. The event resulted in doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care visit. Therapeutic measures were taken as a result of the event and included treatment with Epi pen injection. The patient had no COVID prior vaccination and has not been tested for COVID post vaccination. The outcome of the event was recovered on an unspecified date.  Information about lot/batch number has been requested.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. Medical history, concurrent and conditions and concomitant medications were not provided. On or about 01-SEP-2015, the patient was inoculated with ZOSTAVAX for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 01-OCT-2015, the patient was treated at a medical center for the onset of a severe vesicular rash accompanied by weakened immune symptoms, which was diagnosed as herpes zoster, or shingles. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Additional information has been requested.
the patient had been experiencing cough hoarse throat and fever as high as 104.9 F/the patient thought he may have covid-19 disease; the patient had been experiencing cough hoarse throat and fever as high as 104.9 F/the patient thought he may have covid-19 disease; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date in Apr2021 (Lot number was not reported) as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient reported that he received his first injection of the Pfizer COVID-19 vaccine about 3 weeks ago (in Apr2021). For the past 8 days (in May2021), the patient had been experiencing cough hoarse throat and fever as high as 104.9 F. The patient thought he may have covid-19 disease but he had not been tested. The patient asked that if he should cancel his second Pfizer covid-19 vaccine or not since he may have covid-19 infection. Events outcome was unknown.  Information on the lot/batch number has been requested. Follow-up attempts completed. No further information expected.
Received Expired Dose; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose). On 03-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided by reporter. No treatment information was provided by reporter.
Sharp pain - right side of head; right eye, ear, neck and shoulder pain, shortness of breath, intermittent fevers, chills.
Pt started to faint and then had a seizure. The patient awoke from seizure and 1 minute later had another seizure. EMS arrived and took the patient to a hospital facility.
Received flu vaccine in mass screening clinic. Walked back to office felt "funny" dizziness, felt throat discomfort, monitored. No SOB, stable vx. Benadryl 25mg po. stable. No rash, no SOB. Previous admits to feeling anxious prior to shot so took Xanox-because of anxiety about getting a vaccine. Known diabetic did not take blood sugar. Walked to ED in f/u for monitoring. Left after 15 mi didn't want to and not further problem Called 10/29/02 no further problems.
On 3/11/10 pt. received 3 vaccines that were not needed. She had already had them. The PHOA failed to print out the immunization screen from PTB MIS, so the nurse did not know she had already had them. Called and spoke with house parent - no side effects noted, no problems.
Pt received vaccine and immediately became dizzy and fainted briefly, during this time she urinated. She stayed seated and I helped her sit back and relax. after a minute or so she became nauseous and vomited twice over the next 5 minutes.  blood pressure stayed around 85/55 for the next 10 minutes before leveling at 90/55. She did not know what it usually is, she left accompanied by a friend 30 minutes after vaccine feeling better. I will follow up with her on 8/12/21
severe lymphedema in both arms; This is a spontaneous report from a contactable pharmacist. A female patient of an unspecified age received bnt162b2 (BNT162B2, Solution for injection), via an unspecified route of administration on an unspecified date as an unspecified dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced severe lymphedema in both arms on an unspecified date. Outcome of the event was unknown.  Information about lot/batch number has been requested.  Follow-up (16Apr2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
His arm is very sore; He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move); He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move); This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (His arm is very sore), MYALGIA (He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move)) and ARTHRALGIA (He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move)) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced PAIN IN EXTREMITY (His arm is very sore), MYALGIA (He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move)) and ARTHRALGIA (He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move)). At the time of the report, PAIN IN EXTREMITY (His arm is very sore), MYALGIA (He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move)) and ARTHRALGIA (He has a little bit of muscular and joint discomfort (feels like tight, like sleeping too long and need to move)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was reported.
- Febrile illness. - Generalized skin rash (topical chicken pox rash). - Bilateral Otitis Media.
02/05/22 presents to ED for "AMS". PMHx of "seizure, craniotomy (2008), hypothyroidism, HTN"
Patient complained of muscle soreness and nausea after administration. Two days after pt appeared to have allergic reaction. He called the pharmacy and stated he had redness and swelling around his eyes, one eye he decribed as "droopy". He also complained of burning, tingling, and itching throughout his body that would come intermittently.
RASH, SKIN ERUPTION AND REDNESS. 12/8/09 ER records received for date 11/30/09. DX: urticaria Chief c/o diffused rash, throat closing after H1N1 vax. Pt states h/o reaction to seasonal/flu vax.
Red, scattered Rash on the morning after injection. Mother reports on the left back/torso area. At the end of the day, mother noted rash had spread to the Left leg and foot. Itching. On 8/30/18, after OTC BENADRYL, rash had not improved and was beginning to spread to right side of body and child c/o sore throat.
Difficulty breathing; Developed a red hives like rash on her  shoulder blade and back; site of injection now has just a few bumps; Developed a red hives like rash on her site of injection; Nausea; Vomiting; Upset stomach; Her arm was sore and it hurt; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Her arm was sore and it hurt), DYSPNOEA (Difficulty breathing), ABDOMINAL DISCOMFORT (Upset stomach), RASH (Developed a red hives like rash on her  shoulder blade and back) and NAUSEA (Nausea) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced PAIN IN EXTREMITY (Her arm was sore and it hurt). On 01-Feb-2021, the patient experienced ABDOMINAL DISCOMFORT (Upset stomach), NAUSEA (Nausea) and VOMITING (Vomiting). On 02-Feb-2021, the patient experienced DYSPNOEA (Difficulty breathing). 02-Feb-2021, the patient experienced RASH (Developed a red hives like rash on her  shoulder blade and back), VACCINATION SITE SWELLING (site of injection now has just a few bumps) and VACCINATION SITE RASH (Developed a red hives like rash on her site of injection). The patient was treated with ONDANSETRON (ZOFRAN [ONDANSETRON]) at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Her arm was sore and it hurt), DYSPNOEA (Difficulty breathing), ABDOMINAL DISCOMFORT (Upset stomach), RASH (Developed a red hives like rash on her  shoulder blade and back), NAUSEA (Nausea), VOMITING (Vomiting), VACCINATION SITE SWELLING (site of injection now has just a few bumps) and VACCINATION SITE RASH (Developed a red hives like rash on her site of injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.
This spontaneous report as received from a Registered Nurse refers to a 17 weeks old patient. The reporter reported that the patient was received first dose, oral, of ROTATEQ (lot # was unknown) on 15-OCT-2012 when the patient was 17 weeks old. No adverse effect reported. This is one of the two reports from the same source. The other report was captured in MARRS # 1211USA008789. Additional information has been requested.
It started with rash on the body on April 22, 2021. On April 24, it diminished significantly, but it still continued. On April 26, he aggressively increased the rash throughout the body, including buttocks, groin, ears. It began to itch very the body on April 26, 2021. She was taken for evaluation with a pediatrician that same day.
Sore arm; Red rash that lasted one week after 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Sore arm) and VACCINATION SITE RASH (Red rash that lasted one week after 2nd dose) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025A21A and 042L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA (Sore arm) and VACCINATION SITE RASH (Red rash that lasted one week after 2nd dose). At the time of the report, MYALGIA (Sore arm) and VACCINATION SITE RASH (Red rash that lasted one week after 2nd dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were provided.   This case was linked to MOD-2021-374585 (Patient Link).
VACCINE GIVEN FROM PUNCTURED VIAL THAT HAD BEEN IN THE REFRIGERATOR FOR OVER 6 HOURS; VACCINE HAD BEEN IN THE REFRIGERATOR OVER 6 HOURS; This spontaneous report received from a pharmacist concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 204A21A, and expiry: 07-AUG-2021) dose was not reported, administered on 29-JUN-2021 for prophylactic vaccination. No concomitant medications were reported.  On 29-JUN-2021, the subject experienced vaccine given from punctured vial that had been in the refrigerator for over 6 hours. On 29-JUN-2021, the subject experienced vaccine had been in the refrigerator over 6 hours. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the vaccine given from punctured vial that had been in the refrigerator for over 6 hours and vaccine had been in the refrigerator over 6 hours was not reported. This report was non-serious.
11 year old received 2 doses of Menveo.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA761A, expiry date 30-NOV-2023) for prophylaxis.   Previously administered products included Menveo (1st dose received on 02nd March 2023).   On 09-AUG-2023, the patient received the 2nd dose of Menveo. On 09-AUG-2023, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: 11 year old received 2 doses of Menveo.). The outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 09-AUG-2023 The medical assistant informed that earlier on the day of reporting  an 11 year old patient received a dose of Menveo, but such patient had already received one dose of Menveo back on 2nd March 2023 which led to extra dose administered. The reporter consented to follow up.
Severe headache Severe fatigue Severe muscle pain Could barely get out of bed to use the toilet. No appetite. pushed fluids when awake. took Tramadol, which did not relieve any pain symptoms. Stomach pains on day 4 after eating food.   Returned to work on day 4, after I was forced to stay home an additional day to wait for a negative PCR COVID test, because my symptoms were "COVID".  Will need stronger pain meds for 2nd dose.
Initial report received from a healthcare professional (patient's mother) on 12 December 2012. An 11-year-old male patient, had received an intramuscular dose of ADACEL vaccine (lot number: unknown) on the left deltoid, an intramuscular dose of Flu vaccine (Mfr Unk) (lot number: unknown) on the left deltoid and an intramuscular dose of Meningococcal vaccine (Mfr Unk) (lot number: unknown) on the right deltoid, all of 10 December 2012.
per the EUA we have to report when the patient is admitted to hospital after vaccination. The patient was COVID-19 positive ON 8/12/21
Immediate onset of red rash (macular) on top of head only after vaccines given. Self resolved without treatment over 5-10 minutes. No hives.
I got the worst rash  that basically covered my body from my neck to my legs it so far has lasted 3 weeks and I still have it it is a miserable way to have to live
Muscle pain in affected arm. Pain inc with weight bearing, extension, pushing, pulling. Pain onset began with injection.